Author:
Davis Sharon E.,Zabotka Luke,Desai Rishi J.,Wang Shirley V.,Maro Judith C.,Coughlin Kevin,Hernández-Muñoz José J.,Stojanovic Danijela,Shah Nigam H.,Smith Joshua C.
Funder
U.S. Food and Drug Administration
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Toxicology
Reference121 articles.
1. World Health Organization. What is pharmacovigilance? [cited 22 Jul 2022]. Available at: https://www.who.int/teams/regulation-prequalification/regulation-and-safety/pharmacovigilance.
2. Hauben M, Aronson JK. Defining “signal” and its subtypes in pharmacovigilance based on a systematic review of previous definitions. Drug Saf. 2009;32:99–110.
3. Coloma PM, Trifiro G, Patadia V, Sturkenboom M. Postmarketing safety surveillance: where does signal detection using electronic healthcare records fit into the big picture? Drug Saf. 2013;36:183–97.
4. US Food and Drug Administration. Questions and answers on FDA’s adverse event reporting system (FAERS). 2018. Available at: https://www.fda.gov/drugs/surveillance/questions-and-answers-fdas-adverse-event-reporting-system-faers.
5. European Medicines Agency. EudraVigilance system overview [cited 25 Aug 2022]. Available at: https://www.ema.europa.eu/en/human-regulatory/research-development/pharmacovigilance/eudravigilance/eudravigilance-system-overview.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献